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SUPPLEMENTARY NOTES
ABSTRACT:
Vascular targeting agents (VTA) are new types of anticancer drugs that act on existing tumor vasculature, causing vascular disruption, which ultimately leads to extensive ischemic tumor cell death. Interesting findings showed that VTA killed cells predominantly in the more hypoxic tumor center, as a consequence of hemorrhagic necrosis after vascular collapse, whereas the better perfused peripheral rim was less affected. This apparently limits the effectiveness of such agents and rapid regrowth of tumor residues occurs. However, these findings suggest the possibility and promise of a combination of VTA with treatments specifically targeting the viable tumor rim. Radiation can certainly be expected to be most effective against the well-perfused and oxygenated cell populations at the peripheries of the tumors. One major goal of this project is to fully understand and precisely assess the dynamic changes in blood perfusion and oxygenation after VTA, so that we may predict response and optimize the therapy. I propose to use in vivo MRI to measure and assess physiological changes, e.g. tumor blood perfusion and dynamic tissue oxygenation, in the tumors before and after treatment. I believe non-invasive MRI approaches may provide a valuable prognostic tool to predict the response of specific breast tumors to VTA. 
SUBJECT TERMS
Introduction:
Tumor growth, survival and metastasis depend critically on the development of new blood vessels (1). Thus, inhibiting the growth of new blood vessels, i.e., antiangiogenesis, should prevent growth and metastasis of the primary tumor (1, 2). In addition to the focus on the antiangiogenic approaches, vascular targeting, directly attacking the existing neovasculature, is an alternative strategy against the tumor blood vessel network. Tubulin binding agents, e.g., combretastatin A-4-phosphate (CA4P) represent one kind of vascular targeting agent (VTA) (3, 4) . Promising preclinical studies have shown that such agents selectively cause tumor vascular shutdown and subsequently trigger a cascade of tumor cell death in experimental tumors (4, 5) . However, survived tumors in a thin viable rim usually regrow in spite of induction of massive necrosis. Thus, a combination of VTAs with additional conventional therapeutic approaches will be required (6, 7) . To better understand the mode of action, and hence, optimize such combinations, we plan to apply in vivo MR imaging approaches to monitoring physiological changes in response to VTA administration. Dynamic contrast enhanced (DCE) MRI based on the transport properties of gadolinium-DTPA (Gd-DTPA) is the most commonly used imaging approach to study tumor vascular perfusion and permeability (8, 9) . For combination with radiotherapy, measurement of tumor oxygen dynamics will be especially important since hypoxia affects radiation response. By applying 19 F FREDOM (Fluorocarbon Relaxometry using Echo planar imaging for Dynamic Oxygen Mapping) MRI (10), dynamic tumor oxygenation can be monitored following the treatment with CA4P. Based on pathophysiological changes monitored by MRI, optimum scheme of the combined radiation and CA4P will be designed and experimental treatment will be performed on the syngeneic rat breast tumors.
Body:
The Statement of Work in this project had two major tasks: Task 1. To assess vascular and oxygen dynamics in response to VTA, Months 1-18. a. In vivo MRI assessment of vascular and oxygen dynamics in response to VTA, Months 1-18 b. To study morphological and biological changes of tumor vasculature and hypoxia at cellular and molecular levels in response to VTA, Months 1-18. Task 1 was completed during the Years 1 and 2.
Task 2. Experimental tumor therapy, Month 19-36 Task 2 is ongoing.
While we have not completed all tasks within the original three year time table, we requested and were granted a 1 year no additional cost extension. I believe remaining tasks will be completed successfully.
Progress in Task 2:
a. Learn and become proficient in operating state of the art irradiation system (AccuRay).
Completed.
b. Design therapeutic protocol based on the MR and histological findings: compare the order and timing of the combined therapy (CA4-P 100mg/kg, i.p., irradiation 30 Gy single dose).
Completed.
Radiation dose: While a 30 Gy single dose was proposed originally, we found this dose was well over the TCD 50 for the proposed 13762NF breast tumor. A 10 Gy single dose was then investigated. Results showed that this dose also significantly inhibited tumor growth (Fig. 1) . To study potential effects by adding CA4P, we decided to further lower the radiation dose to 5 Gy.
CA4P dose:
Based on the MRI studies, a dose of 30 mg/kg induced significant reduction in tumor vascular perfusion/permeability and tissue pO 2 (11) . Therefore, we decided to use this dose instead of proposed 100 mg/kg to investigate experimental treatment. Order and timing of the combination: Our MRI results from Years 1 and 2 have shown that tumor blood perfusion/permeability decreased significantly to ~30% of baseline pretreatment level at 2 h after CA4P (30 mg/kg, i.p.) infusion, which recovered fully after 24 h in a thin peripheral region, but not the tumor center (11) . More importantly, dynamic tumor regional pO 2 , which is well recognized to correlate closely with radiation outcome, was evaluated by 19 F MRI. Tumor pO 2 was found to decline within 60 min, become significantly lower at 90 min, and decrease further at 2 h after CA4P infusion. Some regional recovery was seen 24 h later but the pO 2 was still significantly lower than the pretreatment level. However, oxygen breathing at this point modified tumor pO 2 significantly, which resulted in essential elimination of tumor hypoxia (Fig. 2) (11) . Based on these observations, we decided to administer CA4P (30 mg/kg) on Day 1, and 5 Gy radiation on Day 2, while having animals breathe 100% O 2 from 20 min before to the end of radiation. All the MRI findings have been confirmed by histological and immunohistological studies (11) . Previous studies by others have demonstrated that administration of VTA 1 h post radiation produced better improvements in tumor response than other combination schemes. Here, we plan to test our combination approach on the 13762NF tumors. Tumor volume change (normalized mean ± s.e.) versus time curve was plotted, as shown in Fig. 3 . The results showed that a single dose (5 Gy) radiation alone inhibited tumor growth significantly (p < 0.05). While significant growth delay was achieved during the first 3 days after CA4P (30 mg/kg, i.p.), tumors started to regrow from Day 3 and caught up with the Control group rapidly on Day 7. The approach with CA4P 1 h post radiation (IR + CA4P) showed no beneficial effects over the IR alone by Day 10. However, tumors in this group seemed to stop growing after Day 10 while the IR alone tumors started to grow rapidly on Day 10. Unfortunately, longer term of growth delay in these tumors could not be achieved because of tumor ulceration. Our approach (CA4P + IP + O 2 ), which is designed based on the results of tumor pO 2 dynamics monitored by MRI, showed significantly slower tumor growth rate from Day 3 than other groups (p < 0.05).
In addition to the 13762NF subline, we proposed to perform studies on two other sublines of 13762: PAM-CTX and MTLn2. However, we could not obtain these two sublines. Instead, we decided to use human breast MDA-MB-231 tumor. The MDA-MB-231 cells were transfected stably with firefly luciferase. Extensive MRI and bioluminescent imaging (BLI) studies were performed to monitor physiological change in response to CA4P. In good agreement with the 13762NF line, DCE MRI revealed significant reduction in tumor vascular perfusion/permeability (Fig. 4) . Comparable results were obtained by cheaper and high throughput BLI approach (Fig. 5 ). T1-weighted  T2-weighted  T1 contrast  T1-weighted  T2-weighted  T1 contrast   8 before (left) and 2 h after (right) CA4P (120 mg/kg) i.p. injection. A normalized contrast enhanced image at 30 s after a bolus injection of Gd-DTPA-BMA acquired before and 2 h after treatment, respectively is superimposed on the T1-weighted image. Significantly decreased signal enhancement, compared to pretreatment, was observed 2 h after i.p. injection of CA4P. 
Key Research Accomplishments
• Experimental therapy
Based on in vivo study of tumor physiological dynamics evaluated by MRI, we designed a treatment scheme to administer CA4P 24 h before a single dose radiation plus oxygen inhalation. The results showed significantly slower tumor growth in this treatment group than those in other groups.
• Assessment of tumor perfusion dynamics in the human breast tumors in response to the vascular targeting agent, Combretastatin A4 phosphate, by in vivo MR approaches Similar to our previous data of rat 13762NF tumor, DCE MRI showed significant reduction in perfusion and permeability of human MDA-MB-231 breast tumors 2 h after administration of CA4P.
• High throughput bioluminescent imaging evaluation of tumor perfusion in response to CA4P
Significant reduction in signal intensity after infusion of CA4P correlates well with decrease in tumor perfusion monitored by MRI.
• Correlation of MR findings with histological studies Consistent with MRI and BLI findings, histological study of tumor perfusion using Hoechst dye 33342 showed a significant reduction in perfused vessels at 2hr after CA4P, which recovered 24 h later.
Reportable Outcomes
Years 1 and 2: Two peer-reviewed papers and five published conference proceedings. 
Conclusion:
Based on the data of in vivo tumor perfusion and oxygenation dynamics in response to the vascular targeting agent, combretastatin A-4-phosphate (CA4P) evaluated by MRI, we successfully designed a scheme to combine the radiation treatment and CA4P to treat breast tumors. This is the major goal of the proposed project. Moreover, the pathophysiological information will be especially useful for designing a complicated scheme, which usually involves combination of fractionated radiation and multiple dose of systemic chemotherapy at clinical settings. I am confident that the proposed project will be fulfilled by the next term.
